Cargando…
Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study
BACKGROUND: Due to different social and epidemiological factors, the eligibility criteria to receive palivizumab prophylaxis may be different between countries, especially in “otherwise healthy” late preterm infants. METHODS: We analyzed an Italian database of young children referred to emergency de...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845497/ https://www.ncbi.nlm.nih.gov/pubmed/27112952 http://dx.doi.org/10.1186/s13052-016-0252-9 |
_version_ | 1782428958813323264 |
---|---|
author | Silvestri, Michela Marando, Francesca Costanzo, Anna Maria di Luzio Paparatti, Umberto Rossi, Giovanni A. |
author_facet | Silvestri, Michela Marando, Francesca Costanzo, Anna Maria di Luzio Paparatti, Umberto Rossi, Giovanni A. |
author_sort | Silvestri, Michela |
collection | PubMed |
description | BACKGROUND: Due to different social and epidemiological factors, the eligibility criteria to receive palivizumab prophylaxis may be different between countries, especially in “otherwise healthy” late preterm infants. METHODS: We analyzed an Italian database of young children referred to emergency departments for acute lower respiratory tract infection (ALRI) during the RSV season over a four year period, when the use of palivizumab as prophylaxis for RSV disease was not widespread in premature infants. The demographic and environmental characteristics and the RSV positivity (RSV(+)) in hospitalized and not-hospitalized patients were compared. In the data analysis we divided children according to their chronologic age (age) and their week gestational age (wGA). RESULTS: Out of the 100 children evaluated, 68 were infants (≤12 month-age): 7.5 and 20.6 % were in the <29 and 29- < 32 wGA groups respectively, and 72.0 % in the 32- < 35 wGA group. Positive hospitalized-to-not-hospitalized ratios were found in all three wGA groups, progressively decreasing (from 4.0 to 1.2), with increasing wGA (p = 0.35). The percentage of hospitalized infants that were also RSV(+) was also progressively decreasing (from 40.0 to 28.6 % and 18.4 %) with increasing wGA (p = 0.43). In the >12 month-age group (N = 32), there was positive hospitalized-to-not-hospitalized ratio only in the <29 wGA group with a low RSV(+) frequency (<29 %) in all wGA groups. In the ≤12 month-age group, 41 infants were evaluated with a ≤6 month-age and 27 with a >6–12 month-age. A positive hospitalized-to-not-hospitalized ratios was found in all wGA groups in ≤6 month-age infants, despite a low RSV(+) frequency in the 29- < 32 and 32- < 35 wGA group. In the >6-12 month-age group, all infants with a <29 and 29- < 32 wGA were hospitalized with a relatively high RSV(+) frequency whilst the 32- < 35 wGA group showed a negative hospitalized-to-not-hospitalized ratio with a lower RSV(+) frequency. CONCLUSIONS: The hospitalized-to-not-hospitalized ratios and RSV(+) frequency in the first 12 months of age in infants born prematurely confirm the vulnerability of these children for clinically important RSV infection, most notably in the <32 wGA category. |
format | Online Article Text |
id | pubmed-4845497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48454972016-04-27 Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study Silvestri, Michela Marando, Francesca Costanzo, Anna Maria di Luzio Paparatti, Umberto Rossi, Giovanni A. Ital J Pediatr Research BACKGROUND: Due to different social and epidemiological factors, the eligibility criteria to receive palivizumab prophylaxis may be different between countries, especially in “otherwise healthy” late preterm infants. METHODS: We analyzed an Italian database of young children referred to emergency departments for acute lower respiratory tract infection (ALRI) during the RSV season over a four year period, when the use of palivizumab as prophylaxis for RSV disease was not widespread in premature infants. The demographic and environmental characteristics and the RSV positivity (RSV(+)) in hospitalized and not-hospitalized patients were compared. In the data analysis we divided children according to their chronologic age (age) and their week gestational age (wGA). RESULTS: Out of the 100 children evaluated, 68 were infants (≤12 month-age): 7.5 and 20.6 % were in the <29 and 29- < 32 wGA groups respectively, and 72.0 % in the 32- < 35 wGA group. Positive hospitalized-to-not-hospitalized ratios were found in all three wGA groups, progressively decreasing (from 4.0 to 1.2), with increasing wGA (p = 0.35). The percentage of hospitalized infants that were also RSV(+) was also progressively decreasing (from 40.0 to 28.6 % and 18.4 %) with increasing wGA (p = 0.43). In the >12 month-age group (N = 32), there was positive hospitalized-to-not-hospitalized ratio only in the <29 wGA group with a low RSV(+) frequency (<29 %) in all wGA groups. In the ≤12 month-age group, 41 infants were evaluated with a ≤6 month-age and 27 with a >6–12 month-age. A positive hospitalized-to-not-hospitalized ratios was found in all wGA groups in ≤6 month-age infants, despite a low RSV(+) frequency in the 29- < 32 and 32- < 35 wGA group. In the >6-12 month-age group, all infants with a <29 and 29- < 32 wGA were hospitalized with a relatively high RSV(+) frequency whilst the 32- < 35 wGA group showed a negative hospitalized-to-not-hospitalized ratio with a lower RSV(+) frequency. CONCLUSIONS: The hospitalized-to-not-hospitalized ratios and RSV(+) frequency in the first 12 months of age in infants born prematurely confirm the vulnerability of these children for clinically important RSV infection, most notably in the <32 wGA category. BioMed Central 2016-04-26 /pmc/articles/PMC4845497/ /pubmed/27112952 http://dx.doi.org/10.1186/s13052-016-0252-9 Text en © Silvestri et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Silvestri, Michela Marando, Francesca Costanzo, Anna Maria di Luzio Paparatti, Umberto Rossi, Giovanni A. Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study |
title | Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study |
title_full | Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study |
title_fullStr | Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study |
title_full_unstemmed | Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study |
title_short | Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study |
title_sort | respiratory syncytial virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in italy: a retrospective analysis from the osservatorio study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845497/ https://www.ncbi.nlm.nih.gov/pubmed/27112952 http://dx.doi.org/10.1186/s13052-016-0252-9 |
work_keys_str_mv | AT silvestrimichela respiratorysyncytialvirusassociatedhospitalizationinprematureinfantswhodidnotreceivepalivizumabprophylaxisinitalyaretrospectiveanalysisfromtheosservatoriostudy AT marandofrancesca respiratorysyncytialvirusassociatedhospitalizationinprematureinfantswhodidnotreceivepalivizumabprophylaxisinitalyaretrospectiveanalysisfromtheosservatoriostudy AT costanzoannamaria respiratorysyncytialvirusassociatedhospitalizationinprematureinfantswhodidnotreceivepalivizumabprophylaxisinitalyaretrospectiveanalysisfromtheosservatoriostudy AT diluziopaparattiumberto respiratorysyncytialvirusassociatedhospitalizationinprematureinfantswhodidnotreceivepalivizumabprophylaxisinitalyaretrospectiveanalysisfromtheosservatoriostudy AT rossigiovannia respiratorysyncytialvirusassociatedhospitalizationinprematureinfantswhodidnotreceivepalivizumabprophylaxisinitalyaretrospectiveanalysisfromtheosservatoriostudy |